Girolomoni Giampiero, Pastore Saveria, Albanesi Cristina, Cavani Andrea
Second Division of Dermatology and Laboratory of Immunology, Istituto Dermopatico dell'Immacolata, IRCCS, Via dei Monti di Creta 104, 001 67 Rome, Italy.
Curr Opin Investig Drugs. 2002 Nov;3(11):1590-5.
Tumor necrosis factor-a (TNFalpha) plays an important role in the initiation and persistence of inflammation in a variety of skin disorders. The availability of selective TNFalpha blockers has provided new therapeutic opportunities. TNFa inhibitors have been employed with success in treating psoriasis in controlled trials, although further studies are warranted to better define which subgroup of patients can benefit most from this treatment and modalities of combination therapy. In addition, an increasing number of case reports indicates that anti-TNFalpha agents are of value in the treatment of other skin diseases, such as pyoderma gangrenosum and Behcet's syndrome, and in the treatment of graft-versus-host disease.
肿瘤坏死因子-α（TNFα）在多种皮肤疾病的炎症起始和持续过程中起重要作用。选择性TNFα阻滞剂的出现提供了新的治疗机会。在对照试验中，TNFα抑制剂已成功用于治疗银屑病，不过仍需进一步研究以更好地确定哪些患者亚组能从这种治疗及联合治疗模式中获益最多。此外，越来越多的病例报告表明，抗TNFα药物在治疗其他皮肤病（如坏疽性脓皮病和白塞病）以及移植物抗宿主病方面具有价值。
